Renin-Angiotensin System Blockade and Cardiovascular and Renal Protection

American Journal of Cardiology

Volumn 105, Issue 1 SUPPL., 2010, Pages 30A-35A

  Hoogwerf, Byron J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMLODIPINE; CAPTOPRIL; CREATININE; ENALAPRIL; IRBESARTAN; LOSARTAN; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN;

ACUTE HEART INFARCTION; ALBUMINURIA; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG TOLERABILITY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION;

EID: 72049127584     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.10.009     Document Type: Article

References (30)

1. Ferrario C.M., and Strawn W.B. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 98 (2006) 121-128
2. Weir M., Bush C., Anderson D., Zhang J., Keefe D., and Satlin A. Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens 1 (2007) 264-277
3. Williams B., Poulter N.R., Brown M.J., Davis M., McInnes G.T., Potter J.F., Sever P.S., and McG Thom S. Guidelines for the management of hypertension: report of the fourth working party of the British Hypertension Society, 2004 - BHS-IV. J Hum Hypertens 18 (2004) 139-185
4. Pitt B. Clinical trials of angiotensin receptor blockers in heart failure: what do we know and what will we learn?. Am J Hypertens 15 (2002) 22S-27S
5. Kjeldsen S.E., and Julius S. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am Heart J 148 (2004) 747-754
6. Schmieder R.E., Hilgers K.F., Schlaich M.P., and Schmidt B.M. Renin-angiotensin system and cardiovascular risk. Lancet 369 (2007) 1208-1219
7. Giles T. Renin-angiotensin system modulation for treatment and prevention of cardiovascular diseases: toward an optimal therapeutic strategy. Rev Cardiovasc Med 8 suppl 2 (2007) S14-S21
8. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
9. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008) 1547-1559
10. Adler A.I., Stevens R.J., Manley S.E., Bilous R.W., Cull C.A., and Holma R.R. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63 (2003) 225-232
11. Gerstein H.C., Mann J.F.E., Yi Q., Zinman B., Dinneen S.F., Hoogwerf B., Hallé J.P., Young J., Rashkow A., Joyce C., Nawaz S., and Yusuf S. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286 (2001) 421-426
12. Mann J.F., Gerstein H.C., Pogue J., Bosch J., and Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 134 (2001) 629-636
13. Lewis E.J., Hunsicker L.G., Bain R.P., and Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329 (1993) 1456-1462
14. Ravid M., Savin H., Jutrin I., Bental T., Lang R., and Lishner M. Long-term effect of ACE inhibition on development of nephropathy in diabetes mellitus type II. Kidney Int Suppl 45 (1994) S161-S164
15. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., Ritz E., Atkins R.C., Rohde R., and Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
16. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., Remuzzi G., Snapinn S.M., Zhang Z., and Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
17. Parving H.H., Lehnert H., Bröchner-Mortensen J., Gomis R., Andersen S., and Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001) 870-878
18. Makino H., Haneda M., Babazono T., Moriya T., Ito S., Iwamoto Y., Kawamori R., Takeuchi M., Katayama S., and INNOVATION Study Group. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 30 (2007) 1577-1578
19. Makino H., Haneda M., Babazono T., Moriya T., Ito S., Iwamoto Y., Kawamori R., Takeuchi M., Katayama S., and INNOVATION Study Group. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study. Hypertension Res 31 (2008) 657-664
20. Bakris G., Burgess E., Weir M., Davidai G., Koval S., and AMADEO Study Investigators. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 74 (2008) 364-369
21. Mann J.F.E., Schmieder R.E., McQueen M., Dyal L., Schumacher H., Poque J., Wang X., Maggioni A., Budaj A., Chaithiraphan S., et al., ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet 372 (2008) 547-553
22. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
23. The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351 (2004) 2058-2068
24. Pfeffer M.A., McMurray J.J.V., Velazquez E.J., Rouleau J.L., Køber L., Maggioni A.P., Solomon S.D., Swedberg K., Van de Werf F., White H., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
25. McMurray J., Solomon S., Pieper K., Reed S., Rouleau J., Velazquez E., White H., Howlett J., Swedberg K., Maggioni A., et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 47 (2006) 726-733
26. McCall K.L., Craddock D., and Edwards K. Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis. Pharmacotherapy 26 (2006) 1297-1306
27. Yusuf S., Gerstein H., Hoogwerf B., Pogue J., Bosch J., Wolffenbuttel B.H., and Zinman B. Ramipril and the development of diabetes. JAMA 286 (2001) 1882-1885
28. HOPE/HOPE-TOO Study Investigators. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE Study extension. Circulation 112 (2005) 1339-1346
29. The DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 355 (2006) 1551-1562
30. Probstfield J.L., and O'Brien K.D. Progression of cardiovascular damage: the role of renin-angiotensin system blockade. Am J Cardiol suppl 1A (2010) 10A-20A